Making sense of antisense

Canadian Journal of Gastroenterology

Volumn 13, Issue 9, 1999, Pages 745-751

  Yacyshyn, Bruce R ^a   Shanahan Jr , William R ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense oligonucleotides; Crohn's disease; Genes

Indexed keywords

AFOVIRSEN; ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; DOUBLE STRANDED DNA; FOMIVIRSEN; GENE EXPRESSION MODULATOR 132; GENE EXPRESSION MODULATOR 92; ISIS 3521; MESSENGER RNA; PHOSPHOROTHIOIC ACID DERIVATIVE; TRECOVIRSEN; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; CROHN DISEASE; GENE CONTROL; GENE REPLICATION; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; META ANALYSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RESTENOSIS; RETINITIS; REVIEW; RHEUMATOID ARTHRITIS; RNA TRANSLATION; SOLID TUMOR; ULCERATIVE COLITIS;

EID: 0033405738     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/1999/154140     Document Type: Review

References (30)

1. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978;75:280-4.
2. Ts'o POP, Miller PS, Greene JJ. Nucleic acid analogs with targeted delivery at chemotherapeutic agents. In: Cheng YC, Goz B, Minicoff M, eds. Development of Target-Oriented Anticancer Drugs. New York: Raven Press, 1983:189.
3. Heidenreich O, Kang SH, Xu X, Nerenberg M. Application of antisense technology to therapeutics. Mol Med Today 1995;1:128-33.
4. Helene C, Toulme JJ. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1990;1049:99-125.
5. Geary RS, Leeds JM, Henry SP, Monteith DK, Levin AA. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 1997;12:383-93.
6. Chiang MY, Chan H, Zounes MA, Freier SM, Lima WF, Bennett CF. J Biol Chem 1991;266:18162-71.
7. Crooke ST, Bennett CF. Progress in antisense oligonucleotide therapeutics. Ann Rev Pharmacol Toxicol 1996;36:107-29.
8. Bennett CF. Antisense oligonucleotides: Is the glass half full or half empty? Biochem Pharmacol 1998;55:9-19.
9. Agrawal S, Jiang Z, Zhao Q, et al. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci USA 1997;94:2620-5.
10. Monia BP, Lesnik EA, Gonzales C, et al. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 1992;268:14514-22.
11. De Clercq E, Eckstein E, Merigan TC. Interferon induction increased through chemical modification of a synthetic polyribonucleotide. Science 1969;165:1137-9.
12. Levin AA, Monteith DK, Leeds JM, et al. Toxicity of oligodeoxynucleotide therapeutic agents. In: Crooke ST, ed. Antisense Research and Application, vol 131. Berlin: Springer, 1998:169-215.
13. Sheehan JP, Lan HC. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 1998;92:1617-25.
14. Henry SP, Giclas PC, Leeds J, et al. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 1997;281:810-6.
15. Nicklin PM, Craig SJ, Phillips JA. Pharmacokinetic properties of phosphorothioates in animals - absorption, distribution, metabolism, and elimination, vol 131. In: Crooke ST, ed. Antisense Research and Application. Berlin: Springer, 1998:141-68.
16. Agrawal S, Zhang R. Pharmacokinetics and bioavailability of oligonucleotides following oral and colorectal administration in experimental animals, vol 131. In: Crooke ST, ed. Antisense Research and Application. Berlin: Springer, 1998:525-43.
17. Anderson KP, Fox MC, Brown-Driver V, Martin MJ, Azad RF. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob Agents Chemother 1996;40:2004-11.
18. Lieberman RM, Orellana J. Safety and efficacy of fomivirsen sodium (ISIS 2922) for CMV retinitis in AIDS patients. 4th Conference on Retroviruses and Opportunistic Infections, Washington, January 26-29, 1997:758a. (Abst)
19. Muccioli C, Goldstein DA. Johnson DW, et al. Fomivirsen safety and efficacy in the treatment of CMV retinitis: A phase 3, controlled, multicenter study comparing immediate versus delayed treatment. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998;224a. (Abst)
20. Ho PTC, Parkinson DR. Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol 1997;24:187-202.
21. Orr RM, Monia BP. Antisense therapy for cancer. Curr Res Mol Ther 1998;1:102-8.
22. Yazaki T, Ahmad S, Chahlavi A, et al. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol 1996;50:236-42.
23. Neumanaitis J, Von Hoff DD, Holmlund J, Dorr A, Eckhardt SG. Phase I/pharmacokinetic (PK) trial of a protein kinase C-alpha antisense oligonucleotide, ISIS 3521 (CGP 64128A), administered thrice weekly. Proc Am Soc Clin Oncol 1998;17:211a. (Abst)
24. Sikic BI, Yuen AR, Advani R, et al. Antisense oligonucleotide therapy targeted to protein kinase C-alpha (ISIS 3521/CGP 64128A) by 21 day infusion: results of the phase 1 trial and activity in ovarian carcinomas. Proc Am Soc Clin Oncol 1998;17:429a. (Abst)
25. Holmlund J, Neumanaitis J, Schiller J, Dorr A, Kisner D. Phase I trial of c-raf antisense oligonucleotide ISIS 5132 (CGP 69846A) by 21-day continuous intravenous infusion (CIV) in patients with advanced cancer. Proc Am Soc Clin Oncol 1998;17:210a. (Abst)
26. O'Dwyer PJ, Stevenson JP, Gallagher M, et al. Phase I/pharmacokinetic/pharmacodynamic trial of raf-1 antisense ODN (ISIS 5132, CGP 69846A). Proc Am Soc Clin Oncol 1998;17:210a. (Abst)
27. Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997;349:1137-41.
28. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998;114:1133-42.
29. Watson JD, Crick FHC. Molecular structure of nucleic acids: A structure for deoxyribose nucleic acid. Nature 1953;171:737-8.
30. Merino E, Balbas P, Puente JL, Bolivar F. Antisense overlapping open reading frames in genes from bacteria to humans. Nucleic Acids Res 1994;22:1903-8.